Related Experiment Video
Updated: Mar 2, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis
Victoria Divino1, Sudeep Karve2, Andrew Gaughan2
1QuintilesIMS, Fairfax, VA 22031, USA.
Insights
Treatment for hairy cell leukemia (HCL) shows that many patients initiate first-line therapy, often with cladribine, which appears to offer a durable response in this rare blood cancer.
Area of Science:
- Hematology
- Oncology
- Epidemiology
Background:
- Hairy cell leukemia (HCL) is a rare B-cell chronic lymphoid leukemia.
- Understanding treatment patterns is crucial for optimizing patient care and outcomes.
Purpose of the Study:
- To describe the real-world treatment patterns for hairy cell leukemia (HCL) in a large, nationally representative US patient population.
- To analyze the utilization of first- and second-line therapies in newly diagnosed HCL patients.
Main Methods:
- Retrospective analysis of adult patients newly diagnosed with HCL between January 1, 2006, and June 30, 2014.
- Data sourced from the QuintilesIMS PharMetrics Plus Health Plan Claims Database, requiring continuous enrollment.
- Treatment patterns were assessed by line of therapy over variable follow-up periods.
Main Results:
- A cohort of 749 HCL patients was analyzed (77.4% male, mean age 55.6 years).
- Only 37.7% of patients initiated first-line therapy, with a mean initiation time of 4.4 months post-diagnosis.
- Cladribine was the predominant first-line treatment (75.5%), with a mean duration of 7.3 days. Second-line treatment was received by 5.1% of patients.
Conclusions:
- Over an average follow-up of 2.7 years, a significant minority of HCL patients initiated first-line therapy.
- First-line therapy, particularly cladribine, appears to be associated with a long-lasting response in hairy cell leukemia patients.
Aim:
Describe hairy cell leukemia (HCL) treatment patterns using a large, nationally representative US database.
Patients & Methods:
Adults newly diagnosed with HCL (1 January 2006 to 30 June 2014) with continuous health plan enrollment ≥180 days pre- and 90 days post-diagnosis were identified from the QuintilesIMS PharMetrics Plus Health Plan Claims Database. Treatment patterns by line of therapy were assessed over the variable follow-up.
Results:
Among 749 HCL patients (77.4% male; mean age 55.6; mean 32.3 months follow-up), only 37.7% initiated first-line therapy during the available follow-up in a mean of 4.4 months following diagnosis; the majority (75.5%) received cladribine (mean duration 7.3 days). Thirty-eight patients (5.1%) received second-line treatment.
Conclusion:
Over 2.7 years follow-up, more than a third of patients initiated first-line therapy which appeared to provide a long-lasting response.
More Related Videos
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018